美国论文代写:Hikma制药

04 5月 美国论文代写:Hikma制药

美国论文代写:Hikma制药

本节确定就其扩展为多国公司Hikma关键战略问题。两个战略工具的开发,最适合的问题分析。
当前战略问题分析
Hikma制药销售品牌和非品牌仿制药。在美国、中东、北非(曼娜)以及美国的一些企业,其紧迫的战略问题都是在美国的:
1。扩张需要更好的现金流:有关于其扩张Hikma的投资和收购成本的担忧。这些投资需要现金流。在扩张的背景下,企业可能有现金短缺,因此需要建立稳固的业务单位,可以提高现金流量扩张业务。这可能是一个威胁,Hikma
2。地方文化:扩展时,Hikma觉得有必要与本土球员的工作,才变得容易接受当地市场。这可能是Hikma的一个威胁。
三.价格和产品组合:Hikma市场药物通过获取不同研究公司,另外有一个研究和开发部门,研究改性剂量。这增加了Hikma的产品组合,使它在市场更好的成本差异。这是实力和产品组合,Hikma认为可以打开国际市场的好机会。
4。品牌市场的需求:曼娜地区的市场是药品的品牌市场。曼娜是新兴市场(沙文,2013)。Hikma面临的威胁和机会。在管理调整到要求Hikma就在曼娜扩张的更好的机会,但是曼娜地区遭受了严重的政治动荡,这可能是一个威胁。
5。通用产品:普通注射和Hikma其他产品在美国的价格基础上,质量的私人和政府医药行业竞争,产品范围和客户服务。仿制药不仅给成本优势,它创造了一个忠实的消费群体(bremms et al,2011)。这给了Hikma在美国的一位,这是它的力量。

美国论文代写:Hikma制药

This section identifies key strategic issues for Hikma with respect to its expansion as a multinational company. Two strategic tools are developed that best suit analysis of the issues.
1.1. Analysis of current Strategic issues
Hikma Pharmaceuticals sells both branded and non-branded generics. Operating in the United States, the Middle East, North Africa (MENA) as well as Europe, some of its pressing strategic issues are:
1. Expansions necessitate better cash flow: There are concerns about the cost of investments and acquisitions for Hikma in its expansions. These investments require cash flow. In the context of an expansion, businesses may have cash shortage and hence needs to have solidly established business units that can improve cash flow for expansion operations. This could be a threat for Hikma
2. Local culture: When expanding Hikma has felt the need to work with local players, only then it becomes accepted easily in local markets. This could be a threat for Hikma.
3. Price and Product Portfolio: Hikma markets drugs by acquiring from different research companies and in addition has a Research and Development divisions that focuses on modified dosages. This has increased Hikma’s product portfolio and gives it better cost differentiation in markets. This is strength and the product portfolio that Hikma holds could open up beter opportunities in international markets.
4. Demands in Branded Markets: Markets in MENA regions are branded markets for Pharmaceuticals. The MENA are emerging market (Sackman, 2013). Hikma faces both threats and opportunities here. In managing to adjust to the demands Hikma has better opportunities with respect to its expansion in MENA, however MENA regions suffer severe political unrest and this could be a threat.
5. Generic Products: Generic injectables and other products of Hikma compete with the private and government pharmaceutical sector in the United States based on price, quality, product range and customer service. Generics not only give cost advantage, it creates a loyal consumer group (Bremms et al, 2011). This has given Hikma a niche in the US and this is its strength。